Literature DB >> 22143939

Localization of FOXP3-positive cells in renal cell carcinoma.

Katharina Sell1, Peter J Barth, Roland Moll, Martin A Thomas, Nadine Zimmer, Ecatarina Oplesch, Michael Gudo, Mark Schrader, Rainer Hofmann, Andres Jan Schrader.   

Abstract

Regulatory T cells (Treg cells), which are lymphocyte subsets capable of suppressing immune responses, appear to play a crucial role in maintaining immune homeostasis and mediating peripheral tolerance. However, Treg cells also accumulate in cancer patients and have been implicated in tumor immune escape. The forkhead box P3 (FOXP3) transcription factor is currently regarded as the most specific and reliable marker for Treg cells in men. We investigated the frequency and characterized the distribution of FOXP3(+) cells in renal cell carcinoma (RCC) patients, focusing on the tumor microenvironment. FOXP3 expression was assessed in kidney tissue samples from 32 RCC patients by reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry. Both conventional and quantitative RT-PCR disclosed higher FOXP3 expression levels in RCC than in adjacent normal renal tissue. Immunohistochemical staining of FOXP3-expressing cells confirmed the accumulation of FOXP3(+) cells in tumor tissue, particularly at the border between malignant and adjacent benign kidney tissues. Our findings indicate that Treg cells accumulate at the tumor invasion zone and could thus be part of an immune escape mechanism of RCC that promotes disease progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22143939     DOI: 10.1007/s13277-011-0283-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

Review 1.  CD4(+) regulatory T cells.

Authors:  S Read; F Powrie
Journal:  Curr Opin Immunol       Date:  2001-12       Impact factor: 7.486

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.

Authors:  Giovanni C Cesana; Gail DeRaffele; Seth Cohen; Dorota Moroziewicz; Josephine Mitcham; John Stoutenburg; Ken Cheung; Charles Hesdorffer; Seunghee Kim-Schulze; Howard L Kaufman
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

4.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

5.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

6.  Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.

Authors:  Zhen Su; Jens Dannull; Axel Heiser; Donna Yancey; Scott Pruitt; John Madden; Doris Coleman; Donna Niedzwiecki; Eli Gilboa; Johannes Vieweg
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

7.  Signatures of human regulatory T cells: an encounter with old friends and new players.

Authors:  Susanne Pfoertner; Andreas Jeron; Michael Probst-Kepper; Carlos A Guzman; Wiebke Hansen; Astrid M Westendorf; Tanja Toepfer; Andres J Schrader; Anke Franzke; Jan Buer; Robert Geffers
Journal:  Genome Biol       Date:  2006       Impact factor: 13.583

8.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Authors:  François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre E Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

9.  CXCR4/CXCL12 expression and signalling in kidney cancer.

Authors:  A J Schrader; O Lechner; M Templin; K E J Dittmar; S Machtens; M Mengel; M Probst-Kepper; A Franzke; T Wollensak; P Gatzlaff; J Atzpodien; J Buer; J Lauber
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  8 in total

1.  Tissue micro arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma.

Authors:  Giosuè Scognamiglio; Monica Cantile; Stefania Scala; Sabrina Cecere; Federica Russo; Francesca Collina; Laura Marra; Francesco Sabbatino; Gerardo Botti; Renato Franco
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  Tissue Micro Arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma.

Authors:  Giosuè Scognamiglio; Monica Cantile; Stefania Scala; Sabrina Cecere; Federica Russo; Francesca Collina; Laura Marra; Francesco Sabbatino; Gerardo Botti; Renato Franco
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 3.  Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.

Authors:  James H Finke; Pat A Rayman; Jennifer S Ko; Judy M Bradley; Sandra J Gendler; Peter A Cohen
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

4.  VHL-dependent alterations in the secretome of renal cell carcinoma: Association with immune cell response?

Authors:  Franziska Stehle; Sandra Leisz; Kristin Schulz; Nicolle Schwurack; Nico Weber; Chiara Massa; Jana Kalich; Corinna Fahldieck; Barbara Seliger
Journal:  Oncotarget       Date:  2015-12-22

5.  Hyper IgE Syndrome and Renal Cell Carcinoma.

Authors:  Neel H Patel; Mark Ferretti; John L Phillips
Journal:  Case Rep Urol       Date:  2017-05-18

Review 6.  The current status of immunobased therapies for metastatic renal-cell carcinoma.

Authors:  Niranjan J Sathianathen; Suprita Krishna; J Kyle Anderson; Christopher J Weight; Shilpa Gupta; Badrinath R Konety; Thomas S Griffith
Journal:  Immunotargets Ther       Date:  2017-12-05

7.  The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.

Authors:  Alexander S Baras; Charles Drake; Jen-Jane Liu; Nilay Gandhi; Max Kates; Mohamed O Hoque; Alan Meeker; Noah Hahn; Janis M Taube; Mark P Schoenberg; George Netto; Trinity J Bivalacqua
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 8.  Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment.

Authors:  Ellen N Scott; Angela M Gocher; Creg J Workman; Dario A A Vignali
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.